Review

gdc0623 (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress gdc0623
Gdc0623, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdc0623/GDC-0623/pmc12077907-196-15-16
Average 94 stars, based on 10 article reviews

gdc0623 - by Bioz Stars, 2026-09

94/100 stars

Images

Mouse Assay:

Article Title: Induced clustering of SHP2-depleted tumor cells in vascular islands restores sensitivity to MEK/ERK inhibition
Article Snippet: .. Mice received daily oral administration (via gavage) of 0.1 ml formulation buffer alone [0.5% Tween 80 (Sigma Aldrich, #P6224) and 0.5% Methyl Cellulose (Sigma-Aldrich, #M0430) in distilled water] or daily oral administration of GDC0623 (MedChemExpress, #HY-15610; 30 mg/kg) in 0.1 ml formulation buffer, or twice/week s.c. inoculation of VEGF-trap (ZALTRAP, ziv-aflibercept; Sanofi-Aventis) 5 mg/kg in PBS or PBS only (0.1 ml). ..

Formulation:

other:

Article Title: Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
Article Snippet: 2012 Jan. 1; 72(1):210-9), GDC0623 (C16H14FIN4O3 as described in MCE MedChem Express; and Hatzivassiliou G, et al. 2013 Nature.

Biomarker Discovery:

Article Title: Induced clustering of SHP2-depleted tumor cells in vascular islands restores sensitivity to MEK/ERK inhibition
Article Snippet: The murine colon carcinoma CT26 cell line (ATCC, CRL-2638) was cultured in RPMI-1640 medium with 10% FCS. .. TNO155 (Investigational Drugs Repository, NCI Division of Cancer Treatment and Diagnosis [DCTD] and MedChemExpress, mLHY-136173), GDC0623 (MedChemExpress, mLHY-15610), or AZD2014 (MedChemExpress, mLHY-HY-15247) inhibitors were solubilized in DMSO at 10 μM and then aliquoted and stored at –80°C. ..

Image Search Results

Figure 2: Comparisons of ALP staining and activities among the control, IL-1β, and GDC0623 groups. (a) Osteoblasts were stained for ALP levels after being induced with an osteogenic diﬀerentiation medium for 7 days (upper lane). Details of ALP staining at day 7 (lower lane). (b) ALP activities were detected after cell induction for 7 days. Data are expressed as mean ± SD for n 3. ∗p < 0.05 versus the control group; #p < 0.05 versus the IL-1β group.

Journal: International journal of endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways.

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Figure 2: Comparisons of ALP staining and activities among the control, IL-1β, and GDC0623 groups. (a) Osteoblasts were stained for ALP levels after being induced with an osteogenic diﬀerentiation medium for 7 days (upper lane). Details of ALP staining at day 7 (lower lane). (b) ALP activities were detected after cell induction for 7 days. Data are expressed as mean ± SD for n 3. ∗p < 0.05 versus the control group; #p < 0.05 versus the IL-1β group.

Article Snippet: To assess protein phosphorylation levels, osteoblasts were cultured in DMEM plus 0.1% FBS overnight and treated with 20 ng/ml IL-1β (RD company) or IL-1β plus 0.1 μM GDC0623 (Selleck, China) or IL-1β plus 5 μM C188-9 (Selleck, China) for 60min.

Techniques: Staining, Control

Figure 3: GDC0623 treatment aﬀected calciﬁed nodule formation and intracellular calcium levels. (a) Mineralized nodules were stained after osteoblast induction in the osteogenic diﬀerentiation medium for 21 days (upper lane), the details of mineralized nodules (lower lane). (b) Intracellular calcium levels were assessed by the calcium assay kit after treatment with the diﬀerentiation medium for 7 days. Data are expressed as mean ± SD for n 3. ∗p < 0.05 versus the control group, #p < 0.05 versus the IL-1β group.

Journal: International journal of endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways.

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Figure 3: GDC0623 treatment aﬀected calciﬁed nodule formation and intracellular calcium levels. (a) Mineralized nodules were stained after osteoblast induction in the osteogenic diﬀerentiation medium for 21 days (upper lane), the details of mineralized nodules (lower lane). (b) Intracellular calcium levels were assessed by the calcium assay kit after treatment with the diﬀerentiation medium for 7 days. Data are expressed as mean ± SD for n 3. ∗p < 0.05 versus the control group, #p < 0.05 versus the IL-1β group.

Techniques: Staining, Calcium Assay, Control

Figure 4: Osteoblastic gene expression proﬁles in osteoblasts after treatment with GDC0623. (a) Osteoblasts were maintained in an osteogenic diﬀerentiation medium containing IL-1β or IL-1β plus GDC0623 for 7 days. qPCR analysis of osteogenic gene expression in osteoblasts was performed, relative to internal control GAPDH and normalized to control cells. (b) Immunocytochemical staining of Runx2, OCN, and Col I in osteoblasts after treatment with IL-1β or GDC0623 plus IL-1β for 7 days. Data are expressed as mean ± SD for n 3. ∗p < 0.05 versus the control group, #p < 0.05 versus the IL-1β groups.

Journal: International journal of endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways.

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Figure 4: Osteoblastic gene expression proﬁles in osteoblasts after treatment with GDC0623. (a) Osteoblasts were maintained in an osteogenic diﬀerentiation medium containing IL-1β or IL-1β plus GDC0623 for 7 days. qPCR analysis of osteogenic gene expression in osteoblasts was performed, relative to internal control GAPDH and normalized to control cells. (b) Immunocytochemical staining of Runx2, OCN, and Col I in osteoblasts after treatment with IL-1β or GDC0623 plus IL-1β for 7 days. Data are expressed as mean ± SD for n 3. ∗p < 0.05 versus the control group, #p < 0.05 versus the IL-1β groups.

Techniques: Gene Expression, Control, Staining

Figure 5: Eﬀects of GDC0623 on osteoblast proliferation were evaluated by protein expression, CCK-8, and EdU staining assays. (a) Expression levels of PCNA and CyclinD1 were investigated by western blot. (b) Osteoblasts were treated with IL-1β or IL-1β plus GDC0623 for 24 h, 48 h, and 72 h. Optical densities of the three groups at 450 nm were determined and analyzed. (c) EdU incorporation assay of the three groups is on the left and statistical analyses of EdU positive cells are on the right. Data are expressed as mean ± SD for n 3. ∗p < 0.05 versus the control group, #p < 0.05 versus the IL-1β group.

Journal: International journal of endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways.

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Figure 5: Eﬀects of GDC0623 on osteoblast proliferation were evaluated by protein expression, CCK-8, and EdU staining assays. (a) Expression levels of PCNA and CyclinD1 were investigated by western blot. (b) Osteoblasts were treated with IL-1β or IL-1β plus GDC0623 for 24 h, 48 h, and 72 h. Optical densities of the three groups at 450 nm were determined and analyzed. (c) EdU incorporation assay of the three groups is on the left and statistical analyses of EdU positive cells are on the right. Data are expressed as mean ± SD for n 3. ∗p < 0.05 versus the control group, #p < 0.05 versus the IL-1β group.

Techniques: Expressing, CCK-8 Assay, Staining, Western Blot, Control

Figure 6: Eﬀects of GDC0623 and C188-9 on MEK-Erk1/2 and Jak-Stat3 signaling pathways and on expression levels of MMP9 and MMP13. Osteoblasts were pretreated with DMEM plus 0.1% FBS overnight and intervened with IL-1β, IL-1β plus GDC0623, and IL-1β plus C188-9 for 60 min. (a–c) Protein levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were analyzed after IL-1β-stimulated osteoblasts had been treated with GDC0623. (d–f) Expression levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were assessed by blocking the Jak-Stat3 pathway with C188-9.

Journal: International journal of endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways.

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Figure 6: Eﬀects of GDC0623 and C188-9 on MEK-Erk1/2 and Jak-Stat3 signaling pathways and on expression levels of MMP9 and MMP13. Osteoblasts were pretreated with DMEM plus 0.1% FBS overnight and intervened with IL-1β, IL-1β plus GDC0623, and IL-1β plus C188-9 for 60 min. (a–c) Protein levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were analyzed after IL-1β-stimulated osteoblasts had been treated with GDC0623. (d–f) Expression levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were assessed by blocking the Jak-Stat3 pathway with C188-9.

Techniques: Protein-Protein interactions, Expressing, Blocking Assay

Comparisons of ALP staining and activities among the control, IL-1 β , and GDC0623 groups. (a) Osteoblasts were stained for ALP levels after being induced with an osteogenic differentiation medium for 7 days (upper lane). Details of ALP staining at day 7 (lower lane). (b) ALP activities were detected after cell induction for 7 days. Data are expressed as mean ± SD for n = 3. ∗ p < 0.05 versus the control group; # p < 0.05 versus the IL-1 β group.

Journal: International Journal of Endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Comparisons of ALP staining and activities among the control, IL-1 β , and GDC0623 groups. (a) Osteoblasts were stained for ALP levels after being induced with an osteogenic differentiation medium for 7 days (upper lane). Details of ALP staining at day 7 (lower lane). (b) ALP activities were detected after cell induction for 7 days. Data are expressed as mean ± SD for n = 3. ∗ p < 0.05 versus the control group; # p < 0.05 versus the IL-1 β group.

Article Snippet: To assess protein phosphorylation levels, osteoblasts were cultured in DMEM plus 0.1% FBS overnight and treated with 20 ng/ml IL-1 β (RD company) or IL-1 β plus 0.1 μ M GDC0623 (Selleck, China) or IL-1 β plus 5 μ M C188-9 (Selleck, China) for 60 min.

Techniques: Staining, Control

GDC0623 treatment affected calcified nodule formation and intracellular calcium levels. (a) Mineralized nodules were stained after osteoblast induction in the osteogenic differentiation medium for 21 days (upper lane), the details of mineralized nodules (lower lane). (b) Intracellular calcium levels were assessed by the calcium assay kit after treatment with the differentiation medium for 7 days. Data are expressed as mean ± SD for n = 3. ∗ p < 0.05 versus the control group, # p < 0.05 versus the IL-1 β group.

Journal: International Journal of Endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways

doi: 10.1155/2021/5720145

Figure Lengend Snippet: GDC0623 treatment affected calcified nodule formation and intracellular calcium levels. (a) Mineralized nodules were stained after osteoblast induction in the osteogenic differentiation medium for 21 days (upper lane), the details of mineralized nodules (lower lane). (b) Intracellular calcium levels were assessed by the calcium assay kit after treatment with the differentiation medium for 7 days. Data are expressed as mean ± SD for n = 3. ∗ p < 0.05 versus the control group, # p < 0.05 versus the IL-1 β group.

Article Snippet: To assess protein phosphorylation levels, osteoblasts were cultured in DMEM plus 0.1% FBS overnight and treated with 20 ng/ml IL-1 β (RD company) or IL-1 β plus 0.1 μ M GDC0623 (Selleck, China) or IL-1 β plus 5 μ M C188-9 (Selleck, China) for 60 min.

Techniques: Staining, Calcium Assay, Control

Osteoblastic gene expression profiles in osteoblasts after treatment with GDC0623. (a) Osteoblasts were maintained in an osteogenic differentiation medium containing IL-1 β or IL-1 β plus GDC0623 for 7 days. qPCR analysis of osteogenic gene expression in osteoblasts was performed, relative to internal control GAPDH and normalized to control cells. (b) Immunocytochemical staining of Runx2, OCN, and Col I in osteoblasts after treatment with IL-1 β or GDC0623 plus IL-1 β for 7 days. Data are expressed as mean ± SD for n = 3. ∗ p < 0.05 versus the control group, # p < 0.05 versus the IL-1 β groups.

Journal: International Journal of Endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Osteoblastic gene expression profiles in osteoblasts after treatment with GDC0623. (a) Osteoblasts were maintained in an osteogenic differentiation medium containing IL-1 β or IL-1 β plus GDC0623 for 7 days. qPCR analysis of osteogenic gene expression in osteoblasts was performed, relative to internal control GAPDH and normalized to control cells. (b) Immunocytochemical staining of Runx2, OCN, and Col I in osteoblasts after treatment with IL-1 β or GDC0623 plus IL-1 β for 7 days. Data are expressed as mean ± SD for n = 3. ∗ p < 0.05 versus the control group, # p < 0.05 versus the IL-1 β groups.

Article Snippet: To assess protein phosphorylation levels, osteoblasts were cultured in DMEM plus 0.1% FBS overnight and treated with 20 ng/ml IL-1 β (RD company) or IL-1 β plus 0.1 μ M GDC0623 (Selleck, China) or IL-1 β plus 5 μ M C188-9 (Selleck, China) for 60 min.

Techniques: Gene Expression, Control, Staining

Effects of GDC0623 on osteoblast proliferation were evaluated by protein expression, CCK-8, and EdU staining assays. (a) Expression levels of PCNA and CyclinD1 were investigated by western blot. (b) Osteoblasts were treated with IL-1 β or IL-1 β plus GDC0623 for 24 h, 48 h, and 72 h. Optical densities of the three groups at 450 nm were determined and analyzed. (c) EdU incorporation assay of the three groups is on the left and statistical analyses of EdU positive cells are on the right. Data are expressed as mean ± SD for n = 3. ∗ p < 0.05 versus the control group, # p < 0.05 versus the IL-1 β group.

Journal: International Journal of Endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Effects of GDC0623 on osteoblast proliferation were evaluated by protein expression, CCK-8, and EdU staining assays. (a) Expression levels of PCNA and CyclinD1 were investigated by western blot. (b) Osteoblasts were treated with IL-1 β or IL-1 β plus GDC0623 for 24 h, 48 h, and 72 h. Optical densities of the three groups at 450 nm were determined and analyzed. (c) EdU incorporation assay of the three groups is on the left and statistical analyses of EdU positive cells are on the right. Data are expressed as mean ± SD for n = 3. ∗ p < 0.05 versus the control group, # p < 0.05 versus the IL-1 β group.

Article Snippet: To assess protein phosphorylation levels, osteoblasts were cultured in DMEM plus 0.1% FBS overnight and treated with 20 ng/ml IL-1 β (RD company) or IL-1 β plus 0.1 μ M GDC0623 (Selleck, China) or IL-1 β plus 5 μ M C188-9 (Selleck, China) for 60 min.

Techniques: Expressing, CCK-8 Assay, Staining, Western Blot, Control

Effects of GDC0623 and C188-9 on MEK-Erk1/2 and Jak-Stat3 signaling pathways and on expression levels of MMP9 and MMP13. Osteoblasts were pretreated with DMEM plus 0.1% FBS overnight and intervened with IL-1 β , IL-1 β plus GDC0623, and IL-1 β plus C188-9 for 60 min. (a–c) Protein levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were analyzed after IL-1 β -stimulated osteoblasts had been treated with GDC0623. (d–f) Expression levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were assessed by blocking the Jak-Stat3 pathway with C188-9.

Journal: International Journal of Endocrinology

Article Title: MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1 β through the MEK-Erk1/2 and Jak/Stat3 Pathways

doi: 10.1155/2021/5720145

Figure Lengend Snippet: Effects of GDC0623 and C188-9 on MEK-Erk1/2 and Jak-Stat3 signaling pathways and on expression levels of MMP9 and MMP13. Osteoblasts were pretreated with DMEM plus 0.1% FBS overnight and intervened with IL-1 β , IL-1 β plus GDC0623, and IL-1 β plus C188-9 for 60 min. (a–c) Protein levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were analyzed after IL-1 β -stimulated osteoblasts had been treated with GDC0623. (d–f) Expression levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were assessed by blocking the Jak-Stat3 pathway with C188-9.

Article Snippet: To assess protein phosphorylation levels, osteoblasts were cultured in DMEM plus 0.1% FBS overnight and treated with 20 ng/ml IL-1 β (RD company) or IL-1 β plus 0.1 μ M GDC0623 (Selleck, China) or IL-1 β plus 5 μ M C188-9 (Selleck, China) for 60 min.

Techniques: Protein-Protein interactions, Expressing, Blocking Assay

Review

gdc0623 (MedChemExpress)

Structured Review

Images

Related Articles

Mouse Assay:

Formulation:

other:

Biomarker Discovery:

Similar Products

Image Search Results